同步放化疗与新辅助动脉化疗治疗中晚期宫颈癌患者临床效果对比  

Curative effect comparison of concurrent radiotherapy and chemotherapy and neoadjuvant arterial chemotherapy in patients with advanced cervical cancer

作　　者：李倩[1] 刘巧玲[2] 武渊[1] 朱必清[1] 陆谔梅[1] 陈静[1] 蒋明华[1] 

机构地区：[1]江苏省肿瘤医院放疗科,江苏南京210009 [2]南京市江宁医院妇产科,江苏南京211100

出　　处：《中国医学装备》2016年第12期88-92,共5页China Medical Equipment

基　　金：江苏省自然科学基金(BK2007553)"放疗中呼吸引起的组织深度波动对吸收剂量的影响研究"

摘　　要：目的:探讨同步放化疗与新辅助化疗对中晚期宫颈癌患者人乳头瘤病毒E6癌蛋白(HPV-E6)、白细胞分化抗原44变异型6(CD44v6)水平及近期临床疗效的影响。方法:选取50例中晚期宫颈癌患者,根据治疗方案不同将其分为观察组和对照组,每组25例。对照组患者采用同步放化疗方案,观察组患者给予1~2轮新辅助动脉化疗,再行同步放化疗。治疗结束后对患者的血清HPV-E6、CD44v6、患者不良反应以及临床疗效进行检测并比较。结果:观察组患者治疗后血清HPV-E6水平和CD44v6水平均低于对照组,其差异有统计学意义(t=6.515,t=2.636;P<0.05);观察组患者不良反应发生率低于对照组,其差异有统计学意义(x^2=5.333,P<0.05);观察组患者临床治疗总有效率高于对照组,其差异有统计学意义(x^2=4.160,P<0.05)。结论:新辅助动脉化疗与同步放化疗相比,能够明显降低中晚期宫颈癌患者HPV-E6水平和CD44v6水平,且不良反应发生率较低,临床疗效较好。Objective： To investigate the effect of concurrent chemoradiotherapy and neoadjuvant chemotherapy on HPV-E6, CD44V6 and short term clinical efficacy of neoadjuvant chemotherapy in patients with advanced cervical cancer. Methods： 50 cases of middle and advanced cervical cancer in our hospital were collected and divided into the control group and the observation group according to the treatment plan with 25 cases in each group. All the patients were female, and the corresponding treatment measures were given to the patients after admission. The patients in the observation group were treated with neoadjuvant chemotherapy of 1-2 wheel, and then concurrent radiotherapy and chemotherapy were performed. The observation group were treated with cisplatin and irinotecan hydrochloride neoadjuvant chemotherapy. After the treatment, the patients＇ serum HPV-E6, CD44V6, adverse reactions and clinical efficacy were detected and compared. Results： Compared with before treatment, the HPV-E6（t=6.515, P〈0.05） and CD44v6（t=2.636, P〈0.05） serum level of the observation group were lower than those of the control group after treatment. The adverse reaction rate of the observation group were lower than those of the control group（x^2=5.333, P〈0.05）, while the clinical total efficiency of the observation group were higher than those of the control group（x^2=4.160, P〈0.05）. Conclusion： Compared with concurrent chemoradiotherapy, neoadjuvant chemotherapy can significantly reduce the level of HPV-E6 and CD44V6 in patients with advanced cervical cancer, and the incidence of adverse reactions is low. The clinical effect is better.

关 键 词：同步放化疗 新辅助动脉化疗 中晚期宫颈癌 人乳头瘤病毒E6 白细胞分化抗原44变异型6 

分 类 号：R737.33[医药卫生—肿瘤]